Terms of availability for SMEs
B CELL DESIGN (BCD) provides innovative solutions for the design and production of human chimeric monoclonal antibodies (of predefined isotype: IgG1, IgA1, IgM or IgE), technologies addressed either to research, diagnostics or therapeutics markets.
The main issue in the diagnostic industry is to solve the problem of supply in specific human sera, as positive controls and calibrators for their diagnostic kits. Plus, for some diseases, patients developed a combined immune response, requiring testing various isotypes. The BCD's expertise acquired with Diagnosis partners allows offering an alternative technology to overcome supplying restraints. We hold technologies for easily and rapidly producing monoclonal human chimeric specific antibodies (IgG1, IgA1 and secretory IgA1, IgM and IgE), by hybridoma cell line systems. By immunization, we generate highly specific monoclonal human chimeric antibodies to various targets. Working with monoclonal antibodies offers a perfect reproducibility of antibodies affinity, allows keeping quality track of all components of the kit, and ensures a complete safety for users because antibodies are produce in a non-human cellular system.
The company strategy is to develop models of humanized transgenic mice producing a predominantly isotype of human antibodies in order to provide a complete panel of antibodies directed against a single target and to mimic the natural human response.
BCD also develops its own therapeutic pipeline, in anti-infectious diseases and in anti-cancer fields and built strong partnerships with academic laboratories (from French institutes (CNRS, INSERM, Universities of Tours, Limoges, Paris) and from Canadian McGill University), with diagnostic companies (bioMérieux, Theradiag, D-Tek) and with pharma company (SANOFI).
BCD develops a new concept of therapeutic IgA and secretory IgA for anti-cancer and anti-infectious diseases immunotherapies. The preferential tropism of class A isotype for mucosal compartments may be the key in mucosal treatment of infectious diseases whose entrance is the mucosal barrier and for digestive or pulmonary cancers. Also its high resistance to digestive enzymes may allow a potential local administration (orally, breathing) anti-infectious diseases or in anti-cancer strategies.
B CELL DESIGN derived the initial technology to directly generate human chimeric secretory IgA (S-IgA), and by purification process, enriched purified fractions of specific S-IgA.
Quality labels and accreditations
Cancer-Bio-Health cluster of competitivity (CBS cluster)
Industrial partnership :
INSERM, CNRS laboratory
Academic laboratories (Tours, Limoges, Paris Universities, strasbourg, IBCP Lyon, GIMAP St Etienne)
McGill University (Canada)